|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
This report summarizes a phase I clinical experience with a gene-therapy strategy that used an E1(-)E3(-) adenovirus (Ad) gene-transfer vector expressing human vascular endothelial growth factor (VEGF) 121 cDNA (Ad(GV)VEGF121.10) to induce therapeutic angiogenesis in the myocardium of individuals with clinically significant coronary artery disease.
|
10430759 |
1999 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We correlated the VEGF response to hypoxia in the monocytes harvested from patients with coronary artery disease with the presence of collaterals visualized during routine angiography.
|
10430770 |
1999 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.
|
10509970 |
1999 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
3 years) with chronic stable angina due to angiographically documented coronary artery disease, all of whom had failed conventional therapy (drugs, PTCA, and/or CABG), were treated with direct myocardial injection of phVEGF(165) via a minithoracotomy.
|
10961959 |
2000 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several clinical trials based on intramyocardial injection of VEGF DNA in patients with otherwise inoperable coronary artery disease and intractable angina pectoris have recently been completed.
|
14728030 |
2001 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results.
|
11133594 |
2001 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Direct intramyocardial administration of VEGF(165)-DNA and VEGF(167)-DNA may result occasionally in an enhancement of collateral vascularization in regions with diffuse peripheral coronary artery disease not surgically amenable.
|
11717016 |
2001 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We administered: 1) Ad(GV)CFTR.10, a vector carrying the normal human CFTR cDNA (3 x 10(7) to 2 x 10(10) particle units (pu)) to airways of individuals with cystic fibrosis (CF); 2) Ad(GV)VEGF121.10, a vector carrying the normal human vascular endothelial growth factor (VEGF)121 cDNA, to the myocardium (4 x 10(8) to 4 x 10(10) pu) of individuals with coronary artery disease (CAD) and to lower extremity muscles (4 x 10(8) to 4 x 10(9.5) pu) of individuals with peripheral vascular disease (PVD); and 3) Ad(GV)CD.10, a vector carrying the Escherichia coli cytosine deaminase gene to skin (7 x 10(7) to 7 x 10(9) pu) and airways (7 x 10(8) to 7 x 10(10) pu) of normal individuals and to liver metastasis (4 x 10(8) to 4 x 10(9) pu) of individuals with colon carcinoma.
|
12349828 |
2002 |
|
Coronary Artery Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
VEGF plasma levels were measured by ELISA in 64 patients undergoing gene transfer of plasmid DNA: intramuscular in 34 patients with peripheral artery disease, and intramyocardial in 30 patients with coronary disease.
|
12228014 |
2002 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, more research including large scaled clinical trials is needed before deciding whether the vascular endothelial growth factor therapy either as a gene or a recombinant slow-release protein formulation therapy can be offered to patients with severe coronary artery disease, which cannot be treated with conventional revascularization.
|
12762479 |
2003 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Catheter-based intracoronary vascular endothelial growth factor (VEGF) gene transfer is a potential treatment for coronary heart disease.
|
12742981 |
2003 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Gene therapy of coronary artery disease with phvegf165--early outcome.
|
14668888 |
2003 |
|
Coronary Artery Disease
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Gene therapy of coronary artery disease with phvegf165--early outcome.
|
14668888 |
2003 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Direct myocardial administration of genes encoding VEGF165 can be an effective method of treatment in patients with chronic and advanced CAD either as a supplementary treatment or as a single therapy.
|
14668888 |
2003 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease.
|
15347709 |
2004 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest a crucial role of VEGF-A in the development of coronary artery disease.
|
15754021 |
2005 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
LHGDN |
Our findings suggest a crucial role of VEGF-A in the development of coronary artery disease.
|
15754021 |
2005 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
VEGF polymorphisms and severity of atherosclerosis.
|
15937083 |
2005 |
|
Coronary Artery Disease
|
0.400 |
Therapeutic
|
disease |
CTD_human |
VEGF polymorphisms and severity of atherosclerosis.
|
15937083 |
2005 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data suggest that the nonconclusive VEGF gene therapy trials chronic coronary artery disease was not due to a preexisting upregulation of VEGF in chronic ischemic myocardium.
|
16627361 |
2006 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A significantly higher frequency of the CC genotype of the -634 C/G VEGF polymorphism was found in the patients with MI compared to the patients without CAD (17.5 vs. 9.2%; p = 0.019), whereas the insertion/deletion VEGF polymorphism failed to yield an association with MI.
|
17264508 |
2007 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) and its receptor KDR (kinase insert domain-containing receptor/fetal liver kinase-1, also called VEGFR2) play critical roles in angiogenesis and vascular repair, which are involved in the progress of coronary heart disease.
|
17707181 |
2007 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Expression profile of total VEGF, VEGF splice variants and VEGF receptors in the myocardium and arterial vasculature of diabetic and non-diabetic patients with coronary artery disease.
|
17961532 |
2008 |
|
Coronary Artery Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The gene encoding vascular endothelial growth factor (VEGF) is associated with differential protein expression and has been investigated in coronary artery disease (CAD) studies.
|
19037583 |
2008 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The influence of genotype on vascular endothelial growth factor and regulation of myocardial collateral blood flow in patients with acute and chronic coronary heart disease.
|
19544222 |
2009 |